The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Serum Galectin-3 Is Elevated in Obesity and Negatively Correlates with Glycosylated Hemoglobin in Type 2 Diabetes
Abstract
CONTEXT: Adipocytes synthesize galectin-3 whose deficiency protects from inflammation associated with metabolic diseases. We aimed to study circulating galectin-3 in obesity and type 2 diabetes (T2D). STUDY DESIGN: Galectin-3 was measured by ELISA in the serum of male normal-weight and overweight controls and T2D patients and in T2D patients of both sexes. Because visceral fat contributes to systemic inflammation, galectin-3 was analyzed in paired samples of human and rodent sc and visceral adipose tissue. Visceral adipose tissue adipokines are released to the portal vein, and galectin-3 was analyzed in portal, hepatic, and systemic venous serum (PVS, HVS, and SVS, respectively) of patients with liver cirrhosis and in patients who underwent surgery for nonhepatic diseases. The effect of metformin on adipocyte galectin-3 was analyzed by immunoblot. RESULTS: Circulating galectin-3 was similarly elevated in T2D and obesity compared with normal-weight individuals and revealed a body mass index-dependent positive correlation with leptin, resistin, IL-6, and age. In T2D patients, galectin-3 was increased in serum of patients with elevated C-reactive protein and negatively correlated with glycated hemoglobin. Metformin treatment was associated with lower systemic galectin-3. Reduced galectin-3 in metformin-incubated human adipocytes indicated that low galectin-3 may be a direct effect of this drug. Galectin-3 was higher in PVS compared with HVS and SVS, suggesting that the splanchnic region is a major site of galectin-3 synthesis. Low galectin-3 in HVS compared with PVS demonstrated hepatic removal. CONCLUSIONS: Systemic galectin-3 is elevated in obesity and negatively correlates with glycated hemoglobin in T2D patients, pointing to a modifying function of galectin-3 in human metabolic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007) · Diabetes · doi:10.2337/db06-1656 · Cited by 1,417 · cited 1×
“Because excess visceral adipose tissue (VAT) is associated with metabolic diseases (22), galectin-3 was also determined in sc and visceral fat and in portal, hepatic, and systemic venous serum (PVS, HVS, and SVS, respectively) to evaluate the contribution of the splanchnic region and the liver to systemic galectin-3 c…”
BackgroundAdipose tissue dysfunction in obesity, diabetes, and vascular diseases
Hajer, G. R., van Haeften, T. W., & Visseren, F. L. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn387 · Cited by 1,410
Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., Okada-Iwabu, M., Kawamoto, S., Kubota, N., Kubota, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1557 · Cited by 1,396
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“Metformin is commonly used to treat diabetic patients, and reduction of body weight, fasting blood glucose, and HbA1c have been reported (33).”
Background
Cited by
Leptin- and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes
Wang, B., Chandrasekera, P., & Pippin, J. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140508121012 · Cited by 506
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
The fibrosis marker galectin‐3 and outcome in the general population
de Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L., Bakker, S. J. L., & van der Harst, P. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02476.x · Cited by 376
Depression in type 1 diabetes was associated with high levels of circulating galectin-3
Melin, E. O., Dereke, J., Thunander, M., & Hillman, M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0108 · Cited by 31
King, D. R., Salako, D. C., Arthur-Bentil, S. K., Rubin, A. E., Italiya, J. B., Tan, J. S., Macris, D. G., Neely, H. K., Palka, J. M., Grodin, J. L., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.050 · Cited by 29
Metadata
- Authors
- Weigert, J., Neumeier, M., Wanninger, J., Bauer, S., Farkas, S., Scherer, M. N., Schnitzbauer, A., Schäffler, A., Aslanidis, C., Schölmerich, J., & Buechler, C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-03-01
- Volume
- 95
- Issue
- 3
- Pages
- 1404-1411
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2082324941
- Cited by
- 198
- References
- 5
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum Galectin-3 Is Elevated in Obesity and Negatively Correlates with Glycosylated Hemoglobin in Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/jc.2009-1619
- The paper
- Weigert, J., Neumeier, M., Wanninger, J., Bauer, S., Farkas, S., Scherer, M. N., Schnitzbauer, A., Schäffler, A., Aslanidis, C., Schölmerich, J., & Buechler, C. (2010). Serum Galectin-3 Is Elevated in Obesity and Negatively Correlates with Glycosylated Hemoglobin in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-1619
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.